Cargando…

The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports

BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report revised the combined assessment, merged the C and D groups into the E group, and revised the initial inhalation therapy recommendation. OBJECTIVES: This study aimed to analyze the future exacerbation and mortal...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Qing, Cheng, Wei, Liu, Cong, Li, Xueshan, Lin, Ling, Peng, Yating, Zeng, Yuqin, Yi, Rong, Liu, Yi, Li, Xin, Chen, Yan, Cai, Shan, Chen, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685753/
https://www.ncbi.nlm.nih.gov/pubmed/38018090
http://dx.doi.org/10.1177/17534666231213715
_version_ 1785151698991316992
author Song, Qing
Cheng, Wei
Liu, Cong
Li, Xueshan
Lin, Ling
Peng, Yating
Zeng, Yuqin
Yi, Rong
Liu, Yi
Li, Xin
Chen, Yan
Cai, Shan
Chen, Ping
author_facet Song, Qing
Cheng, Wei
Liu, Cong
Li, Xueshan
Lin, Ling
Peng, Yating
Zeng, Yuqin
Yi, Rong
Liu, Yi
Li, Xin
Chen, Yan
Cai, Shan
Chen, Ping
author_sort Song, Qing
collection PubMed
description BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report revised the combined assessment, merged the C and D groups into the E group, and revised the initial inhalation therapy recommendation. OBJECTIVES: This study aimed to analyze the future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease (COPD) in various groups based on the GOLD 2017 and GOLD 2023 reports. DESIGN: This is a multicenter and retrospective study. METHODS: Stable COPD patients from the database setup by 12 hospitals were enrolled. The patients were divided into Groups A, B, C, D, and E according to the GOLD 2017 and GOLD 2023 reports. Then, the patients were classified into long-acting muscarinic antagonist (LAMA), long-acting β2-agonist (LABA) + inhaled corticosteroid (ICS), LABA + LAMA, and LABA + LAMA + ICS subgroups. Data on exacerbation and death during 1 year of follow-up were collected. RESULTS: A total of 4623 patients were classified into Group A (15.0%), Group B (37.8%), Group C (7.3%), Group D (39.9%), and Group E (47.2%). The exacerbation, frequent exacerbation, and mortality showed no differences between different inhalation therapies in Groups A and C. Patients treated with LABA + LAMA or LABA + LAMA + ICS had a lower incidence of exacerbation and frequent exacerbation than patients treated with LAMA or LABA + ICS in Groups B, D, and E. The exacerbation, frequent exacerbation, and mortality showed no differences between different inhalation therapies after combining Groups A with C. CONCLUSION: Patients in Group A should be recommended to undergo mono-LAMA, while patients in Groups B and E should be recommended treatment with LABA + LAMA, which is consistent with the GOLD 2023 report. However, it is worth considering merging Groups A and C into a single group and recommending mono-LAMA as the initial inhalation therapy.
format Online
Article
Text
id pubmed-10685753
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-106857532023-11-30 The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports Song, Qing Cheng, Wei Liu, Cong Li, Xueshan Lin, Ling Peng, Yating Zeng, Yuqin Yi, Rong Liu, Yi Li, Xin Chen, Yan Cai, Shan Chen, Ping Ther Adv Respir Dis Original Research BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report revised the combined assessment, merged the C and D groups into the E group, and revised the initial inhalation therapy recommendation. OBJECTIVES: This study aimed to analyze the future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease (COPD) in various groups based on the GOLD 2017 and GOLD 2023 reports. DESIGN: This is a multicenter and retrospective study. METHODS: Stable COPD patients from the database setup by 12 hospitals were enrolled. The patients were divided into Groups A, B, C, D, and E according to the GOLD 2017 and GOLD 2023 reports. Then, the patients were classified into long-acting muscarinic antagonist (LAMA), long-acting β2-agonist (LABA) + inhaled corticosteroid (ICS), LABA + LAMA, and LABA + LAMA + ICS subgroups. Data on exacerbation and death during 1 year of follow-up were collected. RESULTS: A total of 4623 patients were classified into Group A (15.0%), Group B (37.8%), Group C (7.3%), Group D (39.9%), and Group E (47.2%). The exacerbation, frequent exacerbation, and mortality showed no differences between different inhalation therapies in Groups A and C. Patients treated with LABA + LAMA or LABA + LAMA + ICS had a lower incidence of exacerbation and frequent exacerbation than patients treated with LAMA or LABA + ICS in Groups B, D, and E. The exacerbation, frequent exacerbation, and mortality showed no differences between different inhalation therapies after combining Groups A with C. CONCLUSION: Patients in Group A should be recommended to undergo mono-LAMA, while patients in Groups B and E should be recommended treatment with LABA + LAMA, which is consistent with the GOLD 2023 report. However, it is worth considering merging Groups A and C into a single group and recommending mono-LAMA as the initial inhalation therapy. SAGE Publications 2023-11-28 /pmc/articles/PMC10685753/ /pubmed/38018090 http://dx.doi.org/10.1177/17534666231213715 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc-nd/4.0/This article is distributed under the terms of the Creative Commons Attribution-NoDerivs 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits any use, reproduction and distribution of the work as published without adaptation or alteration, provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Song, Qing
Cheng, Wei
Liu, Cong
Li, Xueshan
Lin, Ling
Peng, Yating
Zeng, Yuqin
Yi, Rong
Liu, Yi
Li, Xin
Chen, Yan
Cai, Shan
Chen, Ping
The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports
title The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports
title_full The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports
title_fullStr The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports
title_full_unstemmed The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports
title_short The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports
title_sort future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various gold groups: a focus on the gold 2017 and gold 2023 reports
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685753/
https://www.ncbi.nlm.nih.gov/pubmed/38018090
http://dx.doi.org/10.1177/17534666231213715
work_keys_str_mv AT songqing thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT chengwei thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT liucong thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT lixueshan thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT linling thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT pengyating thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT zengyuqin thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT yirong thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT liuyi thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT lixin thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT chenyan thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT caishan thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT chenping thefutureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT songqing futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT chengwei futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT liucong futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT lixueshan futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT linling futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT pengyating futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT zengyuqin futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT yirong futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT liuyi futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT lixin futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT chenyan futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT caishan futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports
AT chenping futureexacerbationandmortalityofdifferentinhalationtherapiesamongpatientswithchronicobstructivepulmonarydiseaseinvariousgoldgroupsafocusonthegold2017andgold2023reports